Tricyclic-bis-enone derivatives and methods of use thereof

Details Tricyclic-bis-enone derivatives and methods of use thereof Tricyclic-bis-enone derivatives and methods of use thereof

2010-03-11

2011-11-29

Anderson, Rebecca (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C558S429000

Reexamination Certificate

active

08067465

ABSTRACT:
Novel tricyclic-bis-enone derivatives (TBEs) as well as the process for the preparation of such TBEs are provided. Also provided are methods for prevention and/or treatment of cancer, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotropic lateral sclerosis, rheumatoid arthritis, inflammatory bowel disease, and all other diseases whose pathogenesis is believed to involve excessive production of either nitric oxide (NO) or prostaglandins or the overexpression of iNOS or COX-2 genes or gene products. Further, methods for the synthesis of the TBE compounds of the invention utilize cheap commercially available reagents and are highly cost effective and amenable to scale-up. Additional high efficiency synthetic methods that utilize novel intermediates as well as the synthesis of these intermediates are also provided. Furthermore, the invention also provides methods for designing novel and water-soluble TBEs.

REFERENCES:
patent: 4395423 (1983-07-01), Neumann
patent: 4808614 (1989-02-01), Hertel
patent: 5013649 (1991-05-01), Wang et al.
patent: 5064823 (1991-11-01), Lee et al.
patent: 5401838 (1995-03-01), Chou
patent: 5426183 (1995-06-01), Kjell
patent: 5464826 (1995-11-01), Grindey et al.
patent: 5521294 (1996-05-01), Wildfeuer
patent: 5597124 (1997-01-01), Kessel et al.
patent: 5603958 (1997-02-01), Morein et al.
patent: 5606048 (1997-02-01), Chou et al.
patent: 5972703 (1999-10-01), Long et al.
patent: 6025395 (2000-02-01), Breitner et al.
patent: 6303569 (2001-10-01), Greenwald et al.
patent: 6326507 (2001-12-01), Gribble et al.
patent: 6485756 (2002-11-01), Aust et al.
patent: 6974801 (2005-12-01), Honda et al.
patent: 7176237 (2007-02-01), Honda et al.
patent: 7265096 (2007-09-01), Gallop et al.
patent: 7288568 (2007-10-01), Gribble et al.
patent: 7435755 (2008-10-01), Konopleva et al.
patent: 2002/0042535 (2002-04-01), Gribble et al.
patent: 2005/0276836 (2005-12-01), Wilson et al.
patent: 2005/0288363 (2005-12-01), Gribble et al.
patent: 2007/0155742 (2007-07-01), Honda et al.
patent: 2008/0220057 (2008-09-01), Gribble et al.
patent: 2009/0093447 (2009-04-01), Konopleva et al.
patent: 10 2005 041613 (2007-03-01), None
patent: 0 272 891 (1988-06-01), None
patent: 0 329 348 (1995-07-01), None
patent: 0 376 518 (1995-11-01), None
patent: 0 576 230 (1996-04-01), None
patent: 0 577 303 (1997-10-01), None
patent: 0 712 860 (2001-12-01), None
patent: WO 91/15498 (1991-10-01), None
patent: WO 98/00173 (1998-01-01), None
patent: WO 98/32762 (1998-07-01), None
patent: WO 99/33483 (1999-07-01), None
patent: WO 99/65478 (1999-12-01), None
patent: WO 00/73253 (2000-12-01), None
patent: WO 01/01135 (2001-01-01), None
patent: WO 02/03996 (2002-01-01), None
patent: WO 02/47611 (2002-06-01), None
patent: WO 03/043631 (2003-05-01), None
patent: WO 03/059339 (2003-07-01), None
patent: WO 2005/042002 (2005-05-01), None
patent: WO 2005/046732 (2005-05-01), None
patent: WO 2006/029221 (2006-03-01), None
patent: WO 2007/005879 (2007-01-01), None
patent: WO 2007/069895 (2007-06-01), None
patent: WO 2008/111497 (2008-09-01), None
patent: WO 2008/136838 (2008-11-01), None
patent: WO 2009/023232 (2009-02-01), None
“CDDO in treating patients with metastatic or unresectable solid tumors or lymphoma,” http://www.clinicaltrials.gov/ct2/show/NCT00352040?term=CDDO&rank=1, Dec. 14, 2008.
“FDA mulls drug to slow late-stage Alzheimer's,” http://www.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/index.html, Retrieved on Sep. 23, 2003.
“Phase IIa trail to determine the effects of bardoxolone methyl on renal function in patients with diabetic nephropathy,” http://www.clinicaltrials.gov/ct2/show/NCT00664027?term=rta&rank=10, Dec. 14, 2008.
“RTA 402 in advanced solid tumors or lymphoid malignancies,” http://www.clinicaltrials.gov/ct2/show/NCT00508807?term=rta&rank=2&show—desc=Y, Dec. 14, 2008.
“Study to assess the safety, tolerability, and pharmacodynamics of RTA 402 in patients with hepatic dysfunction,” http://www.clinicaltrials.gov/ct2/show/NCT00550849?term=rta&rank=4, Dec. 14, 2008.
Abraham and Kappas, “Heme oxygenase and the cardiovascular-renal system,”Free Radic. Biol. Med., 39 (1): 1-25, 2005.
Agarwal and Mehta, “Possible involvement of Bcl-2 pathway in resinoid X receptor alpha-induced apoptosis of HL-60 cells,”Biochem Biophys Res Common, 230(2):251-253, 1997.
Ahmad et al., “Triterpenoid CDDO-Me blocks the NF-κB pathway by direct inhibition of IKKβ on Cys-179”,J. Biol. Chem., 281: 35764-9, 2006.
Akrivakis et al., “Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study,”Anti-Cancer Drugs, 10 (6): 525-531, 1999.
Al-alami et al., “Divergent effect of taxol on proliferation, apoptosis and nitric oxide production in MHH225 CD34 positive and U937 CD34 negative human leukemia cells,”Leukemia Res., 22:939-945, 1998.
Alexander et al., “Synthesis and cytotoxic activity of two novel 1-dodecylthio-2-decyloxypropyl-3-phosphatidic acid conjugates with gemcitabine and cytosine arabinoside,”J. Med. Chem., 46 (19): 4205-4208, 2003.
Ambs et al., “p53 and vascular endothelial growth factor regulate tumor growth of NOS2—expressing human carcinoma cells,”Nat. Med., 4(12):1371-1376, 1998.
Amstutz et al., “Die position 5 im oxotremorin-gerust: eine zentrale stelle fur die steuerung der aktivitat am muscarinischen rezeptor,”Helv. Chim. Acta., 70:2232-2244, 1987.
Andreeff et al., “Expression of bcl-2-related genes in normal and AML progenitors: Changes induced by chemotherapy and cationic acid,”Leukemia, 13:1881-1892, 1999.
Andreeff et al., “PPARgamma nuclear receptor as a novel molecular target in leukemias,”2002 Keystone Symposia, Abstract No. 501, 2002.
Andreeff, “Acute myeloid leukemia,”In: Cancer Treatment, Haskell (Ed.), W. B. Saunders, 911-922, 1995.
Araujo et al., “Systemic rather than local heme oxygenase-1 overexpression improves cardiac allograft outcomes in a new transgenic mouse,”J. Immunol., 171 (3): 1572-1580, 2003.
Ardestani et al., “Effects of dexamethasone and betamethasone as COX-2 gene expression inhibitors on rigidity in a rat model of Parkinson's disease,”Indian J. Pharmacol., 39:235-9, 2007.
Ariga et al., “Role of sphingolipid-mediated cell death in neurodegenerative diseases,”Journal of Lipid Research, 39:1-16, 1998.
Bach, “Heme oxygenase-1 and transplantation tolerance,”Hum. Immunol., 67 (6): 430-432, 2006.
Baeuerle, “NF-κB: ten years after,”Cell, 87:13-20, 1996.
Bagasra et al., “Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis,”Proc. Natl. Acad. Sci. USA, 92:12041-12045, 1995.
Baker et al., “2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase,”J. Med. Chem., 34 (6): 1884, 1991.
Baldwin, “The NF-κB and IκB proteins: new discoveries and insights,”Annu. Rev. Immunol., 14:649-681, 1996.
Balkwill et al., “Smoldering and polarized inflammation in the initiation and promotion of malignant disease,”Cancer Cell, 7 (3): 211-217, 2005.
Bargou et al., “Constitutive nuclear factor κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells,”J. Clin. Invest., 100:2961-2969, 1997.
Barkett and Gilmore, “Control of apoptosis by Rel/NF-κB transcription factors,”Oncogene, 18:6910-6924, 1999.
Barnes and Karin, “Nuclear factor-κB—a pivotal transcription factor in chronic inflammation diseases,”N. Engl. J. Med., 336:1066-1071, 1997.
Beal, “Mitochondria, free radicals, and neurodegeneration,”Curr. Opin. Neurobiol., 6:661-666, 1996.
Beran et al., “Topotecan a

Affiliated with

Also associated with

Rating

Tricyclic-bis-enone derivatives and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tricyclic-bis-enone derivatives and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic-bis-enone derivatives and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4278093